Over the past 8 years, MD Anderson has made significant contributions to cancer clinical cooperative group trials, including robust accrual, scientific and administrative leadership, and mentoring young faculty to participate in and lead these important national trials. These attributes will be applied to the emerging National Clinical Trial Network (NCTN) with even greater emphasis through this Network Lead Academic Participant (LAP) grant, with the following overall aims:
Aim 1) To provide robust participation in and accrual to Network group clinical trials targeting a broad range of adult patients with common as well as rare cancers;
Aim 2) To promote best practices in the conduct of NCTN-sponsored clinical research and ensure high quality and timely submission of clinical trial-related data and materials as required by specific protocols;
Aim 3) To provide scientific and administrative leadership within affiliated Network Groups, including protocol development, publication authorship, participation in Network committees / NCI Central IRB (CIRB), and attendance at Network Group meetings;
and Aim 4) To mentor junior faculty, research personnel, and trainees in the leadership, conduct, analysis, and reporting of NCTN and other clinical trials. This LAP utilizes a Multiple Principal Investigator (PI) Plan to apply the demonstrated and complementary cooperative group leadership skills and expertise of 3 investigators: Dr. Cathy Eng, Dr. Kelly Hunt, and Dr. Ritsuko Komaki. In addition, investigators representing the disciplines of pathology, diagnostic imaging, gynecological oncology, surgery, and translational research will play key roles In cooperative group trial conduct and mentorship of young faculty. Oversight of trial accrual and data quality, fund management, centralized communications, and administrative support will be coordinated through the LAP Operations Center under the leadership of an experienced Program Administrator. An Executive Committee will ensure timely inter-Network group communications, effective study prioritizations, review and resolution of any accrual obstacles or data quality issues, and identification of junior facult across the institution as candidates for mentorship and/or leadership roles in Network clinical trials or committees.

Public Health Relevance

The UT MD Anderson Cancer Center Network Lead Academic Participating (LAP) Site grant will provide scientific and administrative leadership to conduct cancer research within the clinical cooperative groups. With enhanced centralized coordination of related activities, this grant will assist with robust accrual across all cooperatie groups and will assist in the development of innovative cancer treatment options, including the conduct of multidisciplinary clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Internal Medicine/Medicine
United States
Zip Code
Ellis, Matthew J; Suman, Vera J; Hoog, Jeremy et al. (2017) Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 35:1061-1069
Tewari, Krishnansu S; Sill, Michael W; Penson, Richard T et al. (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390:1654-1663
Tsao, Anne S; Moon, James; Wistuba, Ignacio I et al. (2017) Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol 12:1299-1308
Chun, Stephen G; Hu, Chen; Choy, Hak et al. (2017) Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol 35:56-62
Boughey, Judy C; Ballman, Karla V; McCall, Linda M et al. (2017) Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Ann Surg 266:667-676
Caudle, Abigail S; Bedrosian, Isabelle; Milton, Denái R et al. (2017) Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol 24:2925-2934
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Brown, Paul D; Ballman, Karla V; Cerhan, Jane H et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060
Giuliano, Armando E; Ballman, Karla V; McCall, Linda et al. (2017) Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318:918-926
Doostan, Iman; Karakas, Cansu; Kohansal, Mehrnoosh et al. (2017) Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clin Cancer Res 23:7288-7300

Showing the most recent 10 out of 55 publications